Stimulant medications US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Stimulant medications. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Stimulant medications US Medical PG Question 1: A 20-year-old college student presents to the emergency room complaining of insomnia for the past 48 hours. He explains that although his body feels tired, he is "full of energy and focus" after taking a certain drug an hour ago. He now wants to sleep because he is having hallucinations. His vital signs are T 100.0 F, HR 110 bpm, and BP of 150/120 mmHg. The patient states that he was recently diagnosed with "inattentiveness." Which of the following is the mechanism of action of the most likely drug causing the intoxication?
- A. Blocks NMDA receptors
- B. Activates mu opioid receptors
- C. Displaces norepinephrine from secretory vesicles leading to norepinephrine depletion
- D. Binds to cannabinoid receptors
- E. Increases presynaptic dopamine and norepinephrine release from vesicles (Correct Answer)
Stimulant medications Explanation: ***Increases presynaptic dopamine and norepinephrine releases from vesicles***
- The patient's presentation with **insomnia**, feeling "full of energy and focus," **hallucinations**, tachycardia (HR 110 bpm), and hypertension (BP 150/120 mmHg) after taking a drug, especially in the context of a recent diagnosis of "inattentiveness," strongly suggests **amphetamine intoxication**. Amphetamines are commonly prescribed for **ADHD**, and their mechanism involves increasing the release of **dopamine** and **norepinephrine** from presynaptic vesicles.
- This increased release of **catecholamines** leads to the stimulant effects observed, including heightened energy, improved focus, and the adverse effects of agitation, psychosis (hallucinations), and sympathetic overdrive.
*Blocks NMDA receptors*
- Drugs that block **NMDA receptors**, such as **phencyclidine (PCP)** or **ketamine**, can cause dissociative and hallucinatory effects.
- However, the patient's primary complaint of feeling "full of energy and focus" in the context of "inattentiveness" points more towards a classical stimulant rather than a dissociative anesthetic.
*Activates mu opioid receptors*
- Activating **mu opioid receptors** (e.g., by heroin, morphine, fentanyl) typically causes central nervous system **depression**, respiratory depression, miosis, and euphoria, not the stimulant and hyperactive state described.
- The patient's symptoms of increased energy, focus, and elevated vital signs are the opposite of opioid effects.
*Displaces norepinephrine from secretory vesicles leading to norepinephrine depletion*
- This mechanism is characteristic of drugs like **reserpine**, which deplete catecholamines and lead to sedative or antihypertensive effects, not the stimulant and sympathomimetic presentation described.
- Such a mechanism would cause a **decrease** in sympathetic activity, contrary to the patient's elevated heart rate and blood pressure.
*Binds to cannabinoid receptors*
- Binding to **cannabinoid receptors** (e.g., by marijuana)
typically leads to effects such as euphoria, altered perception, impaired memory, and sometimes anxiety or paranoia.
- While hallucinations can occur, the prominent "full of energy and focus" and significant sympathetic activation (tachycardia, hypertension) are not typical of cannabinoid intoxication.
Stimulant medications US Medical PG Question 2: A 25-year-old woman presents to her college campus clinic with the complaint of being unable to get up for her morning classes. She says that, because of this, her grades are being affected. For the past 6 weeks, she says she has been feeling depressed because her boyfriend dumped her. She finds herself very sleepy, sleeping in most mornings, eating more snacks and fast foods, and feeling drained of energy. She is comforted by her friend’s efforts to cheer her up but still feels guarded around any other boy that shows interest in her. The patient says she had similar symptoms 7 years ago for which she was prescribed several selective serotonin reuptake inhibitors (SSRIs) and a tricyclic antidepressant (TCA). However, none of the medications provided any long-term relief. She has prescribed a trial of Phenelzine to treat her symptoms. Past medical history is significant for a long-standing seizure disorder well managed with phenytoin. Which of the following statements would most likely be relevant to this patient’s new medication?
- A. “This medication is known to cause anorgasmia during treatment.”
- B. “You will have a risk for cardiotoxicity from this medication.”
- C. “A common side effect of this medication is sedation.”
- D. “While taking this medication, you should avoid drinking red wine.” (Correct Answer)
- E. “While on this medication, you may have a decreased seizure threshold.”
Stimulant medications Explanation: ***"While taking this medication, you should avoid drinking red wine."***
- Phenelzine is a **monoamine oxidase inhibitor (MAOI)**. MAOIs inhibit the breakdown of **tyramine**, an amine found in fermented foods like red wine, aged cheeses, cured meats, and pickled foods.
- Consuming tyramine-rich foods with an MAOI can lead to a **hypertensive crisis**, characterized by a sudden, severe increase in blood pressure which can cause headaches, palpitations, and potentially stroke.
- This dietary counseling is **essential and immediately actionable** patient education when starting an MAOI.
*"This medication is known to cause anorgasmia during treatment."*
- While sexual dysfunction can occur with many antidepressants, **anorgasmia** is much more common and severe with **SSRIs (Selective Serotonin Reuptake Inhibitors)** than with MAOIs.
- MAOIs like phenelzine have a different mechanism of action and generally have a lower incidence of sexual side effects compared to SSRIs.
*"You will have a risk for cardiotoxicity from this medication."*
- **Cardiotoxicity** is a significant concern with **tricyclic antidepressants (TCAs)**, especially in overdose, due to their effects on cardiac sodium channels and potential for arrhythmias.
- While MAOIs can cause **orthostatic hypotension**, direct cardiotoxicity is not a primary concern with phenelzine.
*"A common side effect of this medication is sedation."*
- Phenelzine is generally considered **activating** rather than sedating, and can sometimes lead to insomnia or agitation.
- The patient's current hypersomnia is a symptom of her **atypical depression**, not a predicted side effect of phenelzine. In fact, phenelzine may help improve this symptom.
*"While on this medication, you may have a decreased seizure threshold."*
- This statement is actually **medically accurate** - MAOIs including phenelzine can lower (decrease) the seizure threshold, meaning they increase seizure risk.
- This is relevant given the patient's seizure disorder managed with phenytoin and warrants monitoring.
- However, the **dietary tyramine restriction** is the more critical and immediately actionable counseling point when initiating MAOI therapy, as hypertensive crisis can occur with the very first exposure to tyramine-rich foods.
Stimulant medications US Medical PG Question 3: A 24-year-old male comes into the psychiatric clinic complaining of consistent sadness. He endorses feelings of worthlessness, anxiety, and anhedonia for the past couple months but denies feeling suicidal. He further denies any past episodes of feeling overly energetic with racing thoughts. Confident of the diagnosis, you recommend frequent talk therapy along with a long-term prescription of a known first-line medication for this disorder. What is the drug and what are some of the most frequently encountered side effects?
- A. Selective serotonin reuptake inhibitor; hypomania, suicidal thoughts
- B. Tricyclic antidepressants; hypomania, suicidal thoughts
- C. Selective serotonin reuptake inhibitor; anorgasmia, insomnia (Correct Answer)
- D. Monoamine oxidase inhibitors; Orthostatic hypotension, weight gain
- E. Tricyclic antidepressants; Orthostatic hypotension, anticholinergic effects
Stimulant medications Explanation: ***Selective serotonin reuptake inhibitor; anorgasmia, insomnia***
- The patient presents with classic symptoms of **major depressive disorder**, including persistent sadness, worthlessness, anxiety, and anhedonia, without any history of manic or hypomanic episodes. **SSRIs** are considered first-line pharmacotherapy for this condition.
- Common side effects of SSRIs include **sexual dysfunction** (e.g., anorgasmia, decreased libido) and **insomnia** or agitation, especially during the initial weeks of treatment.
*Selective serotonin reuptake inhibitor; hypomania, suicidal thoughts*
- While SSRIs are the correct drug class, **hypomania** is not a frequent side effect in patients without bipolar disorder. For patients with bipolar disorder, antidepressant monotherapy can induce hypomania or mania, but this patient denies such episodes.
- **Suicidal thoughts** can occur, particularly in young adults, during the initial phase of antidepressant treatment, but it is less common to frame it as a *frequently encountered side effect* in the general population compared to sexual dysfunction or sleep disturbances.
*Tricyclic antidepressants; hypomania, suicidal thoughts*
- **Tricyclic antidepressants (TCAs)** are generally not first-line due to their less favorable side effect profile compared to SSRIs, including significant anticholinergic effects and cardiovascular risks.
- As with SSRIs, **hypomania** is not a typical frequent side effect in unipolar depression, and while **suicidal thoughts** are a concern with antidepressants, TCAs carry a higher risk of lethality in overdose, making them less preferred initially.
*Monoamine oxidase inhibitors; Orthostatic hypotension, weight gain*
- **Monoamine oxidase inhibitors (MAOIs)** are effective but are typically reserved for **refractory depression** due to their significant drug and food interactions (e.g., tyramine-induced hypertensive crisis).
- While **orthostatic hypotension** and **weight gain** are known side effects of MAOIs, this class is not considered a first-line treatment for major depressive disorder.
*Tricyclic antidepressants; Orthostatic hypotension, anticholinergic effects*
- **TCAs** are indeed associated with side effects such as **orthostatic hypotension** and prominent **anticholinergic effects** (e.g., dry mouth, constipation, blurred vision, urinary retention).
- However, because of these more burdensome side effects and higher toxicity in overdose, TCAs are not generally considered the first-line medication choice, especially when SSRIs are available and safer.
Stimulant medications US Medical PG Question 4: A neurophysiologist describes the mechanism of a specific type of synaptic transmission to his students. While illustrating this, he points out that when the action potential reaches the presynaptic terminal of a chemical synapse, the voltage-gated Ca2+ channels open. Ca2+ ions trigger the release of neurotransmitters from vesicles in the presynaptic terminal. In this type of synaptic transmission, increased cytosolic Ca2+ levels cause the release of a neurotransmitter from small vesicles with dense cores. Which of the following neurotransmitters is most likely to be the one that is released into the synaptic cleft in this type of synapse?
- A. Epinephrine
- B. Glutamate
- C. Glycine
- D. GABA (γ-amino butyric acid)
- E. Norepinephrine (Correct Answer)
Stimulant medications Explanation: ***Norepinephrine***
- **Norepinephrine** is the primary catecholamine neurotransmitter stored in **small vesicles with dense cores** (dense-core vesicles).
- It is released from **sympathetic postganglionic neurons** and central nervous system neurons, particularly from the **locus coeruleus**.
- Dense-core vesicles are the hallmark of catecholaminergic neurons, and norepinephrine is the most abundant neuronal catecholamine.
- The description perfectly matches noradrenergic synaptic transmission.
*Epinephrine*
- While epinephrine is also a catecholamine stored in dense-core vesicles, it functions primarily as a **hormone** released from the **adrenal medulla** (not a neurotransmitter).
- Only a **very small number** of CNS neurons use epinephrine as a neurotransmitter (mainly in medullary regions).
- In the context of synaptic transmission, norepinephrine is far more common.
*Glutamate*
- **Glutamate** is the primary excitatory neurotransmitter in the CNS but is stored in **small, clear synaptic vesicles**, not dense-core vesicles.
- It does not fit the description of dense-core vesicle storage.
*Glycine*
- **Glycine** is an inhibitory neurotransmitter stored in **small, clear synaptic vesicles**.
- Found predominantly in the **spinal cord** and brainstem, not in dense-core vesicles.
*GABA (γ-amino butyric acid)*
- **GABA** is the main inhibitory neurotransmitter stored in **small, clear synaptic vesicles**.
- Not associated with dense-core vesicle storage.
Stimulant medications US Medical PG Question 5: A 22-year-old man, accompanied by his brother, presents to the emergency department with palpitations for the past 30 minutes and nausea for the past hour. When the patient meets the physician, he says, “Doctor, I am the happiest person in the world because I have the best brain possible. It’s just that my heart is saying something, so I came to check with you to see what it is”. The brother says the patient was diagnosed with attention-deficit/hyperactivity disorder (ADHD) 5 years ago. When the doctor asks the patient about his ADHD treatment, he replies, “Doctor, the medicine is wonderful, and I love it very much. I often take one or two tablets extra!” He has no history of a known cardiovascular disorder, alcohol abuse, or smoking. The patient’s temperature is 99.2ºF (37.3ºC), heart rate is 116/minute, respiratory rate is 18/minute, and blood pressure is 138/94 mm Hg. Generalized perspiration is present. Which of the following signs is most likely to be present on ocular examination?
- A. Bilateral optic disc edema
- B. Conjunctival injection
- C. Bilateral foveal yellow spots
- D. Rotatory nystagmus
- E. Dilated pupils (Correct Answer)
Stimulant medications Explanation: ***Dilated pupils***
- This patient presents with symptoms such as **palpitations, nausea, hypertension, tachycardia, and generalized perspiration** following an overdose of his ADHD medication. This strongly suggests **sympathomimetic toxicity**, likely due to stimulant overdose.
- **Stimulants** like those used for ADHD (e.g., methylphenidate, amphetamines) characteristically cause **mydriasis (dilated pupils)** due to their sympathomimetic effects on the autonomic nervous system.
*Bilateral optic disc edema*
- **Bilateral optic disc edema** is typically associated with **increased intracranial pressure**, not directly with sympathomimetic stimulant overdose.
- While hypertension is present, it's usually **severe and prolonged hypertension** that can lead to hypertensive retinopathy and disc edema, which is not the primary ocular sign of acute stimulant toxicity.
*Conjunctival injection*
- **Conjunctival injection (red eyes)** is often seen in conditions like **allergic conjunctivitis, viral conjunctivitis, bacterial conjunctivitis, or glaucoma**, and is also a common sign of **cannabis use**.
- It is **not a typical finding in sympathomimetic stimulant overdose**, which primarily affects adrenergic receptors leading to pupillary dilation.
*Bilateral foveal yellow spots*
- **Bilateral foveal yellow spots** can be a non-specific finding or associated with conditions like **macular degeneration**, certain **retinal dystrophies**, or **tamoxifen retinopathy**.
- This finding is **not characteristic of acute stimulant toxicity** or its cardiovascular effects.
*Rotatory nystagmus*
- **Rotatory nystagmus** is an involuntary eye movement typically associated with **vestibular dysfunction, cerebellar lesions, or certain drug toxicities (e.g., phencyclidine, anticonvulsants)**.
- While some drug intoxications can cause nystagmus, **stimulant overdose typically does not produce rotatory nystagmus** as a primary ocular sign, rather it affects pupillary size.
Stimulant medications US Medical PG Question 6: An 11-year-old boy is brought to a pediatrician by his parents with the complaint of progressive behavioral problems for the last 2 years. His parents report that he always looks restless at home and is never quiet. His school teachers frequently complain that he cannot remain seated for long during class, often leaving his seat to move around the classroom. A detailed history of his symptoms suggests a diagnosis of attention-deficit/hyperactivity disorder. The parents report that he has taken advantage of behavioral counseling several times without improvement. The pediatrician considers pharmacotherapy and plans to start methylphenidate at a low dose, followed by regular follow-up. Based on the side effect profile of the medication, which of the following components of the patient’s medical history should the pediatrician obtain before starting the drug?
- A. Past history of recurrent wheezing
- B. Past history of idiopathic thrombocytopenic purpura
- C. Past history of recurrent fractures
- D. Past history of Kawasaki disease (Correct Answer)
- E. Past history of Guillain-Barré syndrome
Stimulant medications Explanation: ***Past history of Kawasaki disease***
- Methylphenidate, a stimulant, can cause **cardiovascular side effects** such as increased heart rate and blood pressure.
- A history of Kawasaki disease, which can lead to **coronary artery aneurysms** and other cardiac complications, necessitates a thorough cardiac evaluation before initiating stimulant therapy to prevent potentially serious cardiovascular events.
*Past history of recurrent wheezing*
- **Recurrent wheezing** primarily involves the respiratory system and is not typically a contraindication or concern with methylphenidate use.
- While general health is important, there is no direct interaction or exacerbation of asthma/wheezing expected from methylphenidate.
*Past history of idiopathic thrombocytopenic purpura*
- **Idiopathic thrombocytopenic purpura (ITP)** is a hematological disorder affecting platelet count and clotting.
- There is no known direct interaction or significant risk of exacerbation of ITP with methylphenidate.
*Past history of recurrent fractures*
- **Recurrent fractures** may suggest underlying bone density issues or other musculoskeletal conditions.
- Methylphenidate does not directly impact bone health or fracture risk, making this history less relevant for its initiation.
*Past history of Guillain-Barré syndrome*
- **Guillain-Barré syndrome** is an autoimmune disorder affecting the peripheral nervous system, leading to muscle weakness and paralysis.
- While neurological history is generally important, there is no specific contraindication or heightened risk for patients with a history of Guillain-Barré syndrome taking methylphenidate.
Stimulant medications US Medical PG Question 7: An 11-year-old boy is brought to the physician by his mother because of teacher complaints regarding his poor performance at school for the past 8 months. He has difficulty sustaining attention when assigned school-related tasks, does not follow the teachers' instructions, and makes careless mistakes in his homework. He often blurts out answers in class and has difficulty adhering to the rules during soccer practice. His mother reports that he is easily distracted when she speaks with him and that he often forgets his books at school. Physical examination shows no abnormalities. The patient is started on the appropriate first-line therapy. This boy is at increased risk for which of the following conditions?
- A. Elevated blood pressure (Correct Answer)
- B. Serotonin syndrome
- C. Increased BMI
- D. Prolonged QT interval
- E. Decreased perspiration
Stimulant medications Explanation: ***Elevated blood pressure***
- This boy's symptoms are highly suggestive of **ADHD** (Attention-Deficit/Hyperactivity Disorder), which is commonly treated with **stimulant medications** like methylphenidate or amphetamines.
- Stimulants can cause **cardiovascular side effects**, including **elevated blood pressure** and heart rate, warranting regular monitoring.
*Serotonin syndrome*
- **Serotonin syndrome** is a risk associated with medications that increase serotonin levels, such as **SSRIs** or MAO inhibitors, which are not typically first-line for ADHD.
- Characterized by altered mental status, autonomic dysfunction, and neuromuscular abnormalities, symptoms not directly caused by stimulant therapy.
*Increased BMI*
- Medications for ADHD, particularly stimulants, are more commonly associated with **decreased appetite** and **weight loss**, not an increased BMI.
- **Appetite suppression** leading to difficulty gaining weight is a known side effect in children taking these medications.
*Prolonged QT interval*
- While some psychiatric medications can prolong the QT interval (e.g., certain antipsychotics or TCAs), **stimulants** used for ADHD are generally not a primary cause of this.
- **ECG monitoring** may be considered for patients with pre-existing cardiac conditions, but it's not a common direct side effect for healthy individuals on stimulants.
*Decreased perspiration*
- Stimulant medications for ADHD can sometimes lead to **increased sweating** (hyperhidrosis) as a side effect, rather than decreased perspiration.
- **Autonomic nervous system changes** due to stimulants can include enhanced sympathetic activity, which can manifest as increased sweating.
Stimulant medications US Medical PG Question 8: A 9-year-old boy is brought to the physician by his mother because of poor performance in school for the last year. He has difficulty sitting still at his desk, does not follow the teacher's instructions, and frequently blurts out answers in class. He often gets sent outside the classroom for failing to work quietly. At hockey practice, he does not wait his turn and has difficulty listening to his coach's instructions. His mother reports that he is easily distracted when she speaks with him and that he often forgets his books at home. Physical examination shows no abnormalities. Which of the following is the most appropriate pharmacotherapy?
- A. Varenicline
- B. Fluoxetine
- C. Suvorexant
- D. Atomoxetine (Correct Answer)
- E. Risperidone
Stimulant medications Explanation: ***Atomoxetine***
- The patient's symptoms of inattention, hyperactivity, and impulsivity are highly suggestive of **Attention-Deficit/Hyperactivity Disorder (ADHD)**. Atomoxetine is a **non-stimulant medication** that is FDA-approved for the treatment of ADHD in children, adolescents, and adults.
- It works by selectively inhibiting the **norepinephrine transporter**, increasing norepinephrine levels in the prefrontal cortex, which helps improve attention and reduce impulsivity.
*Varenicline*
- **Varenicline** is a medication primarily used for **smoking cessation**, acting as a partial agonist at nicotinic acetylcholine receptors.
- It has no established role in the treatment of ADHD and would not address the patient's symptoms.
*Fluoxetine*
- **Fluoxetine** is a **selective serotonin reuptake inhibitor (SSRI)** commonly used to treat depression, anxiety disorders, and obsessive-compulsive disorder.
- While co-occurring anxiety or depression can happen with ADHD, the primary symptoms presented in the case are classic for ADHD, not primarily mood or anxiety disorders.
*Suvorexant*
- **Suvorexant** is an **orexin receptor antagonist** used for the treatment of insomnia, by blocking the wake-promoting effects of orexin.
- It is not indicated for ADHD and would not improve the patient's inattention or hyperactivity.
*Risperidone*
- **Risperidone** is an **atypical antipsychotic** used to treat conditions like schizophrenia, bipolar disorder, and irritability associated with autism.
- While it can be used for severe behavioral problems, it is not a first-line treatment for ADHD and would carry more significant side effects than ADHD-specific medications.
Stimulant medications US Medical PG Question 9: A 5-year-old boy is brought to the physician by his mother because he does not “listen to her” anymore. The mother also reports that her son cannot concentrate on any tasks lasting longer than just a few minutes. Teachers at his preschool report that the patient is more active compared to other preschoolers, frequently interrupts or bothers other children, and is very forgetful. Last year the patient was expelled from another preschool for hitting his teacher and his classmates when he did not get what he wanted and for being disruptive during classes. He was born at term via vaginal delivery and has been healthy except for 3 episodes of acute otitis media at the age of 2 years. He has met all developmental milestones. His mother has major depressive disorder and his father has Graves' disease. He appears healthy and well nourished. Examination shows that the patient does not seem to listen when spoken to directly. The remainder of the examination shows no abnormalities. Which of the following is the most appropriate next step in treatment?
- A. Methylphenidate
- B. Methimazole
- C. Behavior therapy (Correct Answer)
- D. Fluoxetine
- E. Hearing aids
Stimulant medications Explanation: ***Behavior therapy***
- For **preschool-aged children (ages 4-5 years)** with ADHD symptoms, **behavior therapy** is recommended as the **first-line treatment**.
- This approach focuses on teaching parents and caregivers strategies to manage challenging behaviors and improve communication, promoting positive behavioral changes in the child.
*Methylphenidate*
- **Stimulant medications** like methylphenidate are generally considered **second-line treatment** for ADHD in preschool-aged children.
- While effective, their use in this age group is typically reserved for cases where behavior therapy alone has not yielded sufficient improvement.
*Methimazole*
- **Methimazole** is an **antithyroid medication** used to treat **hyperthyroidism**, such as **Graves' disease**.
- This medication is irrelevant to the child's behavioral symptoms and is used for the father's condition.
*Fluoxetine*
- **Fluoxetine** is a **selective serotonin reuptake inhibitor (SSRI)** primarily used to treat **depression** and **anxiety disorders**.
- While the mother has major depressive disorder, fluoxetine is not indicated for the child's ADHD-like symptoms.
*Hearing aids*
- Although the child has a history of recurrent **otitis media**, there is **no current evidence** of hearing impairment affecting his development or behavior.
- Furthermore, his developmental milestones were met, suggesting that any past hearing issues were transient or did not significantly impact his overall development.
Stimulant medications US Medical PG Question 10: A goalkeeper of a famous soccer team gives an interview with a health agency regarding his childhood. He describes how when he was a child, he would constantly clear his throat in class and the teachers would write a note to his mother with advice to go see an ENT doctor. He complained of being restless, fidgety, and sometimes hyperactive in class, disrupting the environment and causing him many social problems. He would blurt out the answer at times and keep repeating it without any control, leading to some embarrassing timeouts. But he was always nice to his teachers, so he calls it a “benign frustration” rather than aggressively causing distress. He also talked about how his symptoms were dramatically improved with medication. Which of the following is an FDA approved drug for this patient’s most likely condition?
- A. Lithium
- B. Clonazepam
- C. Haloperidol (Correct Answer)
- D. Clonidine
- E. Guanfacine
Stimulant medications Explanation: ***Haloperidol***
- The patient's presentation of constant throat clearing (**motor tics**), blurting out answers and repeating words (**vocal tics**), along with restlessness and hyperactivity, is highly suggestive of **Tourette syndrome**.
- **Haloperidol** is one of the **FDA-approved medications** specifically for Tourette syndrome, along with pimozide and aripiprazole.
- It is a **typical antipsychotic** that effectively treats severe tics through **dopamine D2 receptor blockade**, particularly in the nigrostriatal pathway.
- It remains a gold standard treatment despite potential extrapyramidal side effects.
*Lithium*
- **Lithium** is a **mood stabilizer** used primarily for **bipolar disorder** through its effects on intracellular signaling pathways.
- It has no role in treating Tourette syndrome or tic disorders and is not FDA-approved for this indication.
*Clonazepam*
- **Clonazepam** is a **benzodiazepine** with **GABAergic effects** used for **anxiety disorders**, **panic disorder**, and certain seizure disorders.
- While it may help with comorbid anxiety, it is not a primary treatment for tics and is **not FDA-approved** for Tourette syndrome.
*Clonidine*
- **Clonidine** is an **alpha-2 adrenergic agonist** that can reduce tics, particularly in children with mild to moderate symptoms or comorbid ADHD.
- However, it is **off-label** for Tourette syndrome and not FDA-approved for this indication, though commonly used as a second-line agent.
*Guanfacine*
- **Guanfacine** is also an **alpha-2 adrenergic agonist** similar to clonidine, used primarily for ADHD.
- It may help with tics in an **off-label capacity**, especially when ADHD is comorbid, but it is **not FDA-approved** specifically for Tourette syndrome.
More Stimulant medications US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
